Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bicycle Therapeutics (BCYC) Interest Expenses (2021 - 2025)

Bicycle Therapeutics' Interest Expenses history spans 5 years, with the latest figure at $57000.0 for Q4 2025.

  • For Q4 2025, Interest Expenses rose 9.62% year-over-year to $57000.0; the TTM value through Dec 2025 reached $206000.0, down 88.09%, while the annual FY2025 figure was $206000.0, 88.09% down from the prior year.
  • Interest Expenses reached $57000.0 in Q4 2025 per BCYC's latest filing, up from $44000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $883000.0 in Q2 2022 to a low of $33000.0 in Q3 2024.
  • Average Interest Expenses over 5 years is $576350.0, with a median of $817500.0 recorded in 2022.
  • Peak YoY movement for Interest Expenses: surged 56.7% in 2022, then plummeted 95.95% in 2024.
  • A 5-year view of Interest Expenses shows it stood at $820000.0 in 2021, then rose by 0.73% to $826000.0 in 2022, then dropped by 0.73% to $820000.0 in 2023, then crashed by 93.66% to $52000.0 in 2024, then increased by 9.62% to $57000.0 in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Interest Expenses are $57000.0 (Q4 2025), $44000.0 (Q3 2025), and $54000.0 (Q2 2025).